Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2

Recruiting N/A Interventional Study
Breast Cancer Genetic Disease BRCA2 Mutation
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
300 (estimated)
Sponsor
Centre Hospitalier Universitaire de la Réunion · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In mainland France, breast cancer is the most common cancer in women, with an estimated incidence of over 58,000 new cases. Even if breast cancer is a cancer with a good prognosis, it is responsible for more than 12,000 deaths per year (first cause of death by cancer in women in France). Breast cancer is a multifactorial disease, which results from the interaction between environmental, lifestyle…
Trial Locations

Sorted by distance from Montana

Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Domiciled in Reunion at the time of the diagnosis * Who is diagnosed with a first breast cancer (in situ or invasive) confirmed by anatomopathological examination during the inclusion period Or Who is diagnosed with a second breast cancer (in situ or invasive) confirmed by pat…
Contacts

Mireille IRABE

0262906283

mireille.irabe@chu-reunion.FR

CONTACT